Drug Trial Radar · NCT07210723
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
332
Planned (sponsor's estimate)
Start
Feb 13, 2026
Primary completion
Sep 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Kardigan, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are no approved drugs that are designed specifically to treat genetic or familial DCM. The purpose of this study is to evaluate how well danicamtiv works compared to a placebo (sugar pill that looks like danicamtiv pill but does not contain any danicamtiv) and see how safe it is for people with genetic and familial DCM. In DCM, the heart muscle weakens and enlarges, making it harder for the heart to pump blood; this can happen for different reasons. Some people have DCM because of a change in a gene (called genetic DCM). Others may have DCM that runs in their family, even if no specific gene change is found (called familial DCM). The main goals of the study are: * To assess the effect of danicamtiv on cardiac function using echocardiogram. * To evaluate the impact of danicamtiv on exercise capacity * To evaluate the safety and tolerability of danicamtiv Participants will: * Take danicamtiv or placebo every day for approximately 6 months * Visit the clinic about 12 times for initial evaluation, checkups, tests and follow up
Conditions
- Symptomatic Genetic Dilated Cardiomyopathy
Interventions
danicamtivDrug
Danicamtiv will be administrated twice daily for up to 26 weeks
PlaceboDrug
Placebo will be administrated twice daily for up to 26 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Change from Baseline (Day 1) to Week 26 in left atrial function index in Cohort 1Time frame: 26 weeks
- Part 2: Change from Baseline (Day 1) to Week 26 in peak VO2 in Cohort 1Time frame: 26 weeks
Locations
79 sites in 11 countries. Site status is shown where the registry gives one.
University of Alabama Birmingham
Birmingham, Alabama · Recruiting
Cedars Sinai
Los Angeles, California · Recruiting
University of California, Los Angeles (UCLA) - David Geffen School of Medicine
Los Angeles, California · Not yet recruiting
University of California, San Diego (UCSD) - Medical Center
San Diego, California · Recruiting
UCSF
San Francisco, California · Recruiting
Stanford University Medical Center
Stanford, California · Recruiting
MedStar Washington Hospital Center
Washington D.C., District of Columbia · Recruiting
Mayo Clinic - Jacksonville
Jacksonville, Florida · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
Louisiana State University (LSU) Health Sciences Center
New Orleans, Louisiana · Recruiting
Johns Hopkins Medicine
Baltimore, Maryland · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Henry Ford Health System
Detroit, Michigan · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
Saint Luke's Mid America Heart Institute
Kansas City, Missouri · Recruiting
Washington University in St. Louis
St Louis, Missouri · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
NYU Langone Health
New York, New York · Recruiting
Columbia University Medical Center/ New York Presbyterian Hospital
New York, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
The Lindner Center for Research and Education at The Christ Hospital
Cincinnati, Ohio · Recruiting
The Ohio State University Wexner Medical Center
Columbus, Ohio · Recruiting
Oregon Health & Science University (OHSU)
Portland, Oregon · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
Houston Methodist Hospital
Houston, Texas · Recruiting
AZORG - Campus Moorselbaan
Aalst, Belgium · Recruiting
Universite Libre de Bruxelles (ULB) - Hopital Erasme
Brussels, Belgium · Recruiting
Universitair Ziekenhuis Antwerpen (UZA)
Edegem, Belgium · Recruiting
Jessa Ziekenhuis
Hasselt, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Aarhus University Hospital
Aarhus, Denmark · Recruiting
Rigshospitalet
Copenhagen, Denmark · Recruiting
Odense University Hospital - Odense
Odense, Denmark · Recruiting
CHRU de Tours - Hopital Trousseau
Chambray-lès-Tours, France · Recruiting
CHU de Lille - Institut Coeur Poumon
Lille, France · Not yet recruiting
AP-HP Hopital Pitie-Salpetriere
Paris, France · Recruiting
AP-HP Hopital Europeen Georges Pompidou
Paris, France · Recruiting
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.